<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00539305</url>
  </required_header>
  <id_info>
    <org_study_id>29975-A</org_study_id>
    <secondary_id>R01AG027156</secondary_id>
    <secondary_id>1R01AG027156-01A2</secondary_id>
    <nct_id>NCT00539305</nct_id>
  </id_info>
  <brief_title>Hormone and Information Processing Study</brief_title>
  <acronym>HIP</acronym>
  <official_title>Testosterone Supplementation in Men With MCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of testosterone (T) replacement on
      changes in thinking and memory, as well as mood in older men with mild cognitive impairment
      (MCI) and low T levels. The study will also examine whether taking testosterone has effects
      on biological markers related to Alzheimer's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Natural age related declines in testosterone (T) are associated with decreases in cognitive
      abilities independent of health status. Low T levels over time are associated with increased
      risk for developing Alzheimer's disease (AD). These findings suggest that men with low T
      levels are most at risk for age-related cognitive decline and AD and therefore most likely to
      benefit from T supplementation to prevent the development of AD or age-associated cognitive
      decline. The current study will assess cognition, mood, and cerebral spinal fluid (CSF)
      biomarker response to T supplementation in older men with mild cognitive impairment (MCI) and
      low T levels.

      Participants will be randomized to either receive T treatment or a placebo for six months.
      Participants will come in for about five visits within the span of six months where they will
      complete cognitive &amp; memory tests, fill out mood questionnaires, and have their blood drawn
      to monitor the medication level. A sample of blood will also be taken at one visit to test
      for apolipoprotein E (APOE), which is a genetic risk factor associated with AD. Participants
      will have the option to get a spinal tap in order to measure biological markers associated
      with Alzheimer's disease including beta-amyloid 1-40, 42, total-tau, and
      phosphorylated-tau-181-231. This will require an additional two visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Behavioral &amp; Mood Measure: Profile of Mood States (POMS)</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <description>Values represent self evaluation of vigor-activity. The scale compares t-scores of participants to published norms (range 0-100), and higher scores indicate elevated emotion in subscale. Higher t-scores in vigor-activity subscale are considered favorable. Month 3 and Month 6 values display change from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive Changes Measured by Neuropsychological Tests: Rey Auditory Verbal Learning Test</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <description>Values represent total score in Long Delay Word List Recall. Higher score indicates higher level of functioning (range 0-15). Month 3 and Month 6 indicate change from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geriatric Depression Scale (GDS)</measure>
    <time_frame>Baseline, Month 3, Month 6</time_frame>
    <description>Values represent self evaluation of depression (range 0-30). Higher scores indicate a more depressed mood. Month 3 and Month 6 indicate change from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-Form Health Survey (SF-36)</measure>
    <time_frame>Baseline, Month 3, Month 6</time_frame>
    <description>Self assessment of Physical Functioning in Health Survey. Higher scores indicate a higher level of functioning (range 0-100). Month 3 and 6 values represent change from baseline in subscale.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Study drug; testosterone transdermal gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone gel</intervention_name>
    <description>50-100mg applied topically daily for six months</description>
    <arm_group_label>Study drug; testosterone transdermal gel</arm_group_label>
    <other_name>Solvay Testosterone Gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo gel</intervention_name>
    <description>applied topically daily for six months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male 60-90 years of age

          -  Diagnosis of mild cognitive impairment (MCI)

          -  Low testosterone level

          -  Primary language is English

          -  Availability of an informant who knows the participant well enough to answer questions

          -  Stable medications for the previous 3 months

          -  Normal complete blood count (CBC), and no clinically significant blood chemistry

          -  American Urological Association (AUA) symptom score less than or equal to 19

          -  Body Mass Index (BMI) less than 33 and stable weight in the previous year

        Exclusion Criteria:

          -  Prior history of prostate cancer or prostate specific antigen level greater than
             4.0ng/ml

          -  Peripheral or vascular disease

          -  Significant history of alcohol abuse, current alcohol abuse (more than 2 drinks per
             day), or other substance abuse

          -  History of severe head injury (with loss of consciousness greater than 30 minutes)

          -  Significant neurological illness, such as Parkinson's disease, seizure disorder,
             multiple sclerosis, major stoke

          -  Smokes cigarettes

          -  Major psychiatric illness, such as schizophrenia or bipolar disorder

        Prohibited Medications:

          -  Anti-convulsants

          -  Anti-psychotics

          -  Sedating antihistamines

          -  Sedative/hypnotics

          -  Benzodiazepines

          -  Hormone or testosterone regimens

          -  Gonadotropin-releasing hormone (GNRH) antagonists

          -  Flutamide

          -  Anti-depressants and/or anti-cholinesterase inhibitors, but acceptable if on stable
             dose for 3 months or more
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monique Cherrier, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Puget Sound Health Care Systems</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E, Raskind MA, Brodkin K, Bremner W, Petrova A, LaTendresse S, Craft S. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001 Jul 10;57(1):80-8.</citation>
    <PMID>11445632</PMID>
  </reference>
  <reference>
    <citation>Cherrier MM, Matsumoto AM, Amory JK, Ahmed S, Bremner W, Peskind ER, Raskind MA, Johnson M, Craft S. The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology. 2005 Jan 25;64(2):290-6.</citation>
    <PMID>15668427</PMID>
  </reference>
  <reference>
    <citation>Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, Raskind MA, Craft S. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology. 2005 Jun 28;64(12):2063-8.</citation>
    <PMID>15985573</PMID>
  </reference>
  <reference>
    <citation>Cherrier MM, Matsumoto AM, Amory JK, Johnson M, Craft S, Peskind ER, Raskind MA. Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older men. Psychoneuroendocrinology. 2007 Jan;32(1):72-9. Epub 2006 Dec 4.</citation>
    <PMID>17145137</PMID>
  </reference>
  <reference>
    <citation>Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, Yaffe K, Reback E, Porter V, Swerdloff R, Cummings JL. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol. 2006 Feb;63(2):177-85. Epub 2005 Dec 12.</citation>
    <PMID>16344336</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2007</study_first_submitted>
  <study_first_submitted_qc>October 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2007</study_first_posted>
  <results_first_submitted>March 15, 2013</results_first_submitted>
  <results_first_submitted_qc>July 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2014</results_first_posted>
  <last_update_submitted>July 10, 2014</last_update_submitted>
  <last_update_submitted_qc>July 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Monique Cherrier</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>selective androgen receptor modulators (SARMs)</keyword>
  <keyword>hormone replacement therapy</keyword>
  <keyword>age-associated cognitive decline</keyword>
  <keyword>testosterone supplementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl
testosterone gel : 50-100mg applied topically daily for six months</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Placebo gel : applied topically daily for six months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Substance Use</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl
testosterone gel : 50-100mg applied topically daily for six months</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Placebo gel : applied topically daily for six months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.2" spread="9.1"/>
                    <measurement group_id="B2" value="70.0" spread="7.7"/>
                    <measurement group_id="B3" value="70.5" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Behavioral &amp; Mood Measure: Profile of Mood States (POMS)</title>
        <description>Values represent self evaluation of vigor-activity. The scale compares t-scores of participants to published norms (range 0-100), and higher scores indicate elevated emotion in subscale. Higher t-scores in vigor-activity subscale are considered favorable. Month 3 and Month 6 values display change from baseline.</description>
        <time_frame>Baseline, 3 and 6 months</time_frame>
        <population>Vigor-Activity</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl
testosterone gel : 50-100mg applied topically daily for six months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo gel : applied topically daily for six months</description>
          </group>
        </group_list>
        <measure>
          <title>Behavioral &amp; Mood Measure: Profile of Mood States (POMS)</title>
          <description>Values represent self evaluation of vigor-activity. The scale compares t-scores of participants to published norms (range 0-100), and higher scores indicate elevated emotion in subscale. Higher t-scores in vigor-activity subscale are considered favorable. Month 3 and Month 6 values display change from baseline.</description>
          <population>Vigor-Activity</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7" spread="2.2"/>
                    <measurement group_id="O2" value="55.5" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="2.8"/>
                    <measurement group_id="O2" value="-0.1" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.7"/>
                    <measurement group_id="O2" value="-0.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cognitive Changes Measured by Neuropsychological Tests: Rey Auditory Verbal Learning Test</title>
        <description>Values represent total score in Long Delay Word List Recall. Higher score indicates higher level of functioning (range 0-15). Month 3 and Month 6 indicate change from baseline.</description>
        <time_frame>Baseline, 3 and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl
testosterone gel : 50-100mg applied topically daily for six months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo gel : applied topically daily for six months</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Changes Measured by Neuropsychological Tests: Rey Auditory Verbal Learning Test</title>
          <description>Values represent total score in Long Delay Word List Recall. Higher score indicates higher level of functioning (range 0-15). Month 3 and Month 6 indicate change from baseline.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="1.1"/>
                    <measurement group_id="O2" value="4.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.9"/>
                    <measurement group_id="O2" value="0.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.9"/>
                    <measurement group_id="O2" value="1.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geriatric Depression Scale (GDS)</title>
        <description>Values represent self evaluation of depression (range 0-30). Higher scores indicate a more depressed mood. Month 3 and Month 6 indicate change from baseline.</description>
        <time_frame>Baseline, Month 3, Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl
testosterone gel : 50-100mg applied topically daily for six months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo gel : applied topically daily for six months</description>
          </group>
        </group_list>
        <measure>
          <title>Geriatric Depression Scale (GDS)</title>
          <description>Values represent self evaluation of depression (range 0-30). Higher scores indicate a more depressed mood. Month 3 and Month 6 indicate change from baseline.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="1.3"/>
                    <measurement group_id="O2" value="4.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.5"/>
                    <measurement group_id="O2" value="2.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="1.5"/>
                    <measurement group_id="O2" value="2.7" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short-Form Health Survey (SF-36)</title>
        <description>Self assessment of Physical Functioning in Health Survey. Higher scores indicate a higher level of functioning (range 0-100). Month 3 and 6 values represent change from baseline in subscale.</description>
        <time_frame>Baseline, Month 3, Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl
testosterone gel : 50-100mg applied topically daily for six months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo gel : applied topically daily for six months</description>
          </group>
        </group_list>
        <measure>
          <title>Short-Form Health Survey (SF-36)</title>
          <description>Self assessment of Physical Functioning in Health Survey. Higher scores indicate a higher level of functioning (range 0-100). Month 3 and 6 values represent change from baseline in subscale.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" spread="10.4"/>
                    <measurement group_id="O2" value="85.6" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="9.4"/>
                    <measurement group_id="O2" value="-3.8" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="8.6"/>
                    <measurement group_id="O2" value="-5.4" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl
testosterone gel : 50-100mg applied topically daily for six months</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Placebo gel : applied topically daily for six months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PSA elevated above 4.0 ng/ml</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Emergency room with chest pains</sub_title>
                <description>Pain stopped within 10-15 minutes, patient was not admitted to hospital and is following up with his personal physician.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Monique Cherrier PhD.</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-277-3594</phone>
      <email>cherrier@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

